- Global Pharma News & Resources

Global Tinnitus Drug Pipeline Landscape Report 2021 -

DUBLIN--(BUSINESS WIRE)--The "Tinnitus (Ear Nose Throat Disorders) - Drugs In Development, 2021" report has been added to's offering.

Tinnitus - Drugs In Development, 2021, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape.

Tinnitus is a condition characterized by ringing, swishing, or other noises that originate in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing, buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch.

Report Highlights

Tinnitus - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tinnitus (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tinnitus (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tinnitus (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tinnitus (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders)

Key Topics Covered:


Tinnitus - Overview

  • Tinnitus - Therapeutics Development

Pipeline Overview

  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Tinnitus - Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Tinnitus - Companies Involved in Therapeutics Development

  • AudioCure Pharma GmbH
  • Auris Medical Holding Ltd
  • Autifony Therapeutics Ltd
  • Cognosetta Inc
  • Gateway Biotechnology Inc
  • Knopp Biosciences LLC
  • Otonomy Inc
  • Sensorion SA

Tinnitus - Drug Profiles

  • AC-102
  • AM-102
  • AUT-3
  • CS-0022
  • esketamine hydrochloride
  • gacyclidine
  • GW-103
  • GW-201
  • KB-3061
  • RL-81
  • Small Molecules to Activate KCNQ2 and KCNQ3 for Tinnitus
  • tetrandrine

Tinnitus - Dormant Projects

Tinnitus - Discontinued Products

Tinnitus - Product Development Milestones

Featured News & Press Releases

  • Jun 16, 2021: Light E.N.T. announces first patient enrolled in drug trial for treatment of tinnitus (Ringing Sound in Ear)
  • Apr 05, 2021: Otonomy announces presentation of OTO-313 clinical results at American Neurotology Society Annual Meeting
  • Mar 25, 2021: Otonomy initiates phase 2 clinical trial of OTO-313 in Tinnitus
  • Nov 30, 2020: Otonomy provides update on OTO-313 program
  • Jul 06, 2020: Otonomy reports positive top-line results from phase 1/2 clinical trial of OTO-313 in patients with tinnitus
  • Jun 22, 2020: CogInc receives Bull Ring Accelerator Funding
  • Apr 08, 2020: CogInc awarded AOHL's Flexi grant
  • Jan 10, 2020: Auris Medical announces notice of allowance for European Patent Application
  • Dec 17, 2019: Cognosetta: SBIR grant awarded
  • Sep 13, 2019: Auris Medical receives FDA and EMA Guidance for Keyzilen late-stage clinical development program
  • Aug 26, 2019: Auris Medical announces formation of scientific advisory board for tinnitus programs
  • May 23, 2019: Auris Medical provides update on Keyzilen
  • Apr 25, 2019: Auris Medical provides update on Tinnitus Drug Development Strategy
  • Apr 11, 2019: Otonomy initiates phase 1/2 Clinical Trial of OTO-313 in Tinnitus
  • Feb 06, 2019: Otonomy announces presentation on tinnitus drug OTO-313 at Association for Research in Otolaryngology Annual Meeting


For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 09-Sep-2021